Clinical trials of dual-hormone systems have consistently demonstrated that adding glucagon reduces the incidence of hypoglycaemia compared with insulin-only systems, particularly in high-risk or high-activity scenarios such as exercise and overnight periods [30,43-46]. The gene discussed is INS; the disease is Hypoglycemia.